BACKGROUND: Keratin 17 (K17) is regarded as a basal/myoepithelial cell keratin and is known to be inducible in activated keratinocytes. The high frequency of K17 expression in pancreaticobiliary nonmucinous adenocarcinoma or basal-like breast carcinoma has previously been described. However, its expression in gastric cancer (GC) is controversial. METHODS: We investigated the clinicopathological features and prognostic significance of 192 patients with GC by immunohistochemical staining of tissue microarrays. Analysis of epithelial markers including K17, K14, and K5/6, cell cycle-associated proteins p53, Ki-67, and 14-3-3 sigma, and mucinous phenotype markers including CD10, CDX2, MUC5AC, and MUC6 was performed. RESULTS: Cytoplasmic expression of K17 was observed in 95 (49.5%) of 192 patients with GC. K17 expression positively correlated with lymph node metastasis (P = 0.003) and advanced stages of the disease (P = 0.014). K17 expression was significantly correlated with 14-3-3 sigma expression (P < 0.001) and CD10 expression (P = 0.015). The overall survival rates of patients with K17-positive GC were significantly lower than those with negative K17 expression (50.5 vs. 71.1%, P = 0.004). Univariate analysis revealed that K17 expression confers a poor prognosis in patients with GC (P = 0.004), and it was also an independent prognostic factor in multivariate analysis (P = 0.049). CONCLUSIONS: K17 expression is correlated with tumor progression in GC and may serve as a biomarker for poor prognosis.
BACKGROUND:Keratin 17 (K17) is regarded as a basal/myoepithelial cell keratin and is known to be inducible in activated keratinocytes. The high frequency of K17 expression in pancreaticobiliary nonmucinous adenocarcinoma or basal-like breast carcinoma has previously been described. However, its expression in gastric cancer (GC) is controversial. METHODS: We investigated the clinicopathological features and prognostic significance of 192 patients with GC by immunohistochemical staining of tissue microarrays. Analysis of epithelial markers including K17, K14, and K5/6, cell cycle-associated proteins p53, Ki-67, and 14-3-3 sigma, and mucinous phenotype markers including CD10, CDX2, MUC5AC, and MUC6 was performed. RESULTS: Cytoplasmic expression of K17 was observed in 95 (49.5%) of 192 patients with GC. K17 expression positively correlated with lymph node metastasis (P = 0.003) and advanced stages of the disease (P = 0.014). K17 expression was significantly correlated with 14-3-3 sigma expression (P < 0.001) and CD10 expression (P = 0.015). The overall survival rates of patients with K17-positive GC were significantly lower than those with negative K17 expression (50.5 vs. 71.1%, P = 0.004). Univariate analysis revealed that K17 expression confers a poor prognosis in patients with GC (P = 0.004), and it was also an independent prognostic factor in multivariate analysis (P = 0.049). CONCLUSIONS:K17 expression is correlated with tumor progression in GC and may serve as a biomarker for poor prognosis.
Authors: Luisa F Escobar-Hoyos; Jie Yang; Jiawen Zhu; Julie-Ann Cavallo; Haiyan Zhai; Stephanie Burke; Antonius Koller; Emily I Chen; Kenneth R Shroyer Journal: Mod Pathol Date: 2013-09-20 Impact factor: 7.842
Authors: Mihaela Chivu-Economescu; Denisa L Dragu; Laura G Necula; Lilia Matei; Ana Maria Enciu; Coralia Bleotu; Carmen C Diaconu Journal: Gastric Cancer Date: 2017-03-15 Impact factor: 7.370
Authors: Ivy Moffat; Nikolai Chepelev; Sarah Labib; Julie Bourdon-Lacombe; Byron Kuo; Julie K Buick; France Lemieux; Andrew Williams; Sabina Halappanavar; Amal Malik; Mirjam Luijten; Jiri Aubrecht; Daniel R Hyduke; Albert J Fornace; Carol D Swartz; Leslie Recio; Carole L Yauk Journal: Crit Rev Toxicol Date: 2015-01 Impact factor: 5.635
Authors: Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick Journal: Mol Cell Biol Date: 2013-09-16 Impact factor: 4.272
Authors: Qiang Du; Wusheng Yan; Victoria H Burton; Stephen M Hewitt; Lemin Wang; Nan Hu; Philip R Taylor; Michael D Armani; Sumana Mukherjee; Michael R Emmert-Buck; Michael A Tangrea Journal: Am J Cancer Res Date: 2013-08-14 Impact factor: 6.166